Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 28, 2022 16:02 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect

-- On-track to initiate Phase 2b trial in 4Q 2022, with topline data expected in 1Q 2024 ---- Cash runway extended into 1Q 2025, pending receipt of second tranche from previously announced financing,...
November 28, 2022 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing

ARLINGTON, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
November 08, 2022 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

-- Planning to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Ended Quarter with $52.4 million in Cash;...
November 01, 2022 07:30 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research,...
October 20, 2022 07:30 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Reverse Stock Split

ARLINGTON, Mass., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research,...
September 06, 2022 08:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...
August 19, 2022 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

ARLINGTON, Mass., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as an inducement...
August 18, 2022 16:01 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Announces Distribution of Series D Preferred Stock to Holders of its Common Stock

ARLINGTON, Mass., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA) (“Kala” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the research,...
August 11, 2022 07:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data Expected in 1Q 2024 ---- Received $60M Upfront Payment from Sale of EYSUVIS® and...
August 08, 2022 09:00 ET | Source: Kala Pharmaceuticals, Inc.

Kala Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call

ARLINGTON, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization...